NZ332879A - Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes - Google Patents

Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes

Info

Publication number
NZ332879A
NZ332879A NZ332879A NZ33287997A NZ332879A NZ 332879 A NZ332879 A NZ 332879A NZ 332879 A NZ332879 A NZ 332879A NZ 33287997 A NZ33287997 A NZ 33287997A NZ 332879 A NZ332879 A NZ 332879A
Authority
NZ
New Zealand
Prior art keywords
leptin
diabetes
protein
fragments
treating obesity
Prior art date
Application number
NZ332879A
Inventor
Kamal A Al-Barazanji
Jonathan Robert Sanders Arch
Patrick Camilleri
William Arthur Neville
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9611775.9A external-priority patent/GB9611775D0/en
Priority claimed from GBGB9618540.0A external-priority patent/GB9618540D0/en
Priority claimed from GBGB9703493.8A external-priority patent/GB9703493D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NZ332879A publication Critical patent/NZ332879A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The specification describes the use of a leptin or ob peptide or a functional derivative, analogue or variant thereof, to modulate body weight substantially by means of modulating energy utilisation. Pharmaceuticals containing the ob protein, or functional fragments of it, are formulated for treating obesity or diabetes.
NZ332879A 1996-06-06 1997-06-04 Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes NZ332879A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9611775.9A GB9611775D0 (en) 1996-06-06 1996-06-06 Novel compounds
GBGB9618540.0A GB9618540D0 (en) 1996-09-05 1996-09-05 Novel compounds
GBGB9703493.8A GB9703493D0 (en) 1997-02-20 1997-02-20 Novel compounds
PCT/EP1997/002968 WO1997046585A2 (en) 1996-06-06 1997-06-04 Fragments of leptin (ob protein)

Publications (1)

Publication Number Publication Date
NZ332879A true NZ332879A (en) 2000-09-29

Family

ID=27268305

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ332879A NZ332879A (en) 1996-06-06 1997-06-04 Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes

Country Status (15)

Country Link
EP (1) EP0912609A2 (en)
JP (1) JP2000512137A (en)
KR (1) KR20000016402A (en)
CN (1) CN1221426A (en)
AR (1) AR008765A1 (en)
AU (1) AU3337297A (en)
BR (1) BR9709529A (en)
CA (1) CA2257240A1 (en)
CZ (1) CZ397898A3 (en)
IL (1) IL127153A0 (en)
NO (1) NO985683L (en)
NZ (1) NZ332879A (en)
PL (1) PL330361A1 (en)
TR (1) TR199802534T2 (en)
WO (1) WO1997046585A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756617B2 (en) 1998-07-28 2003-01-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) * 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU782230B2 (en) 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
EP1283878B1 (en) 2000-05-22 2005-07-27 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Receptor-based interaction trap
DE60237100D1 (en) 2001-10-22 2010-09-02 Amgen Inc USE OF LEPTIN FOR THE TREATMENT OF LIPOATROPR PREDICTIVE POSITION AGAINST TREATMENT
CA2535021A1 (en) 2003-09-08 2005-03-17 Applied Research Systems Ars Holding N.V. Use of insp035 to treat fibrotic disease
CN103897066A (en) 2004-02-11 2014-07-02 安米林药品有限责任公司 Hybrid polypeptides with selectable properties
WO2006053883A1 (en) 2004-11-18 2006-05-26 Vib Vzw Fibronectin iii domain as leptin receptor antagonists
EP2392595A1 (en) 2005-02-11 2011-12-07 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable properties
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
ES2319048B1 (en) * 2007-06-20 2010-02-10 Universitat De Les Illes Balears USE OF LEPTINE IN THE TREATMENT OF ALTERATIONS IN FOOD HABITS.
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
GB2451858A (en) * 2007-08-15 2009-02-18 Sergiy Konovchuk Methods of reducing body fat and treating obesity
EP2234992B1 (en) 2007-12-05 2012-02-22 AstraZeneca AB Piperazine derivatives and their use as leptin receptor modulators
EA201000926A1 (en) 2007-12-05 2011-02-28 Астразенека Аб PIPERASINS AS AGENTS AGAINST OBESITY
AU2009254547A1 (en) * 2008-06-04 2009-12-10 Astrazeneca Ab (Publ) New compounds V
JP2011522007A (en) * 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ New pyridine derivatives as leptin receptor modulator mimetics
EP2416797A4 (en) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc Amylin agonist compounds for estrogen-deficient mammals
EP2569326B1 (en) * 2010-05-11 2016-08-10 The U.S.A. as represented by the Secretary, Department of Health and Human Services Peptide-based inhibitor of interleukin-10 or stat-3 activation
CA3138758A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Highly soluble leptins
CN104829707B (en) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 The leptin activity peptide and its encoding gene and application of one CD ring and E spiral region mutations
CN110183530A (en) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 Leptin immunogene, hybridoma, monoclonal antibody, polyclonal antibody and application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2211656A1 (en) * 1995-01-31 1996-08-08 Margret B. Basinski Anti-obesity proteins
WO1996023815A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Ob gene product antibodies
US5552523A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
WO1996031526A1 (en) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Anti-obesity agents
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
IL127153A0 (en) 1999-09-22
PL330361A1 (en) 1999-05-10
AR008765A1 (en) 2000-02-23
NO985683D0 (en) 1998-12-04
TR199802534T2 (en) 1999-03-22
WO1997046585A2 (en) 1997-12-11
CN1221426A (en) 1999-06-30
CZ397898A3 (en) 1999-04-14
JP2000512137A (en) 2000-09-19
KR20000016402A (en) 2000-03-25
CA2257240A1 (en) 1997-12-11
EP0912609A2 (en) 1999-05-06
NO985683L (en) 1998-12-04
BR9709529A (en) 1999-08-10
AU3337297A (en) 1998-01-05
WO1997046585A3 (en) 1998-04-23

Similar Documents

Publication Publication Date Title
NZ332879A (en) Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes
GB2292382B (en) Obesity (OB) peptides capable of modulating body weight of animals, allelic variants, analogs and fragments thereof, derivatives, nucleic acid sequences, vect
EP1231218A3 (en) An appetite-suppressing peptide, its compositions and use
DE69719798D1 (en) PERIPHERAL ADMINISTRATION OF GLP-1 ANALOGS AND DERIVATIVES FOR REGULATING OBESITY
MY132189A (en) Recombinant obese (ob) proteins
NO995044D0 (en) Osteoprotegerin-binding proteins and receptors
EP1194164B8 (en) Prion protein peptides and uses thereof
DK0881906T3 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
AU4397297A (en) Antibody against human parathormone related peptides
EP1077217A3 (en) Neuroactive peptides and their use
SE9603533L (en) Specific peptides for the treatment of diabetes mellitus
SG63615A1 (en) Dna encoding a human calcium channel alpha-ie subunit
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
CA2234263A1 (en) Pharmaceutical composition for treating papillomavirus tumours and infection
US5690869C1 (en) Use of a polymer material on the basis of modified hydrocolloids as covering material
AU2002216551A1 (en) Activity control during dieting
CA2268796A1 (en) Bi-aromatic compounds bound by a heteroethynylene radical and pharmaceutical and cosmetic compositions containing same
DK0990703T3 (en) New polypeptide, its encoding DNA, and its use
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
DE69409961T2 (en) TRIARYLETHYLENE DERIVATIVES FOR THERAPEUTIC USE
AU1879097A (en) Fragments of cr1 and their use
DE69733026D1 (en) CYCLIN E SPECIFIC DESIGNS AND COMPLEXES
AU6723898A (en) Composition for treating tanned leather, and its preparation
AU7145891A (en) Nailing system for treating fractures, particularly cervico-trochanterian and pertrochanterian fractures
AU6977994A (en) Peptides derived from human interleukin-2 for use in medicine

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired